<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04834024</url>
  </required_header>
  <id_info>
    <org_study_id>MIL62-CT301</org_study_id>
    <nct_id>NCT04834024</nct_id>
  </id_info>
  <brief_title>MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma</brief_title>
  <official_title>A Multi-center, Open Label, Phase III Study to Evaluate the Efficacy and Safety of MIL62 Plus Lenalidomide Versus Lenalidomide in Subjects With Follicular Lymphoma Refractory to Rituximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Mabworks Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Mabworks Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase III trial aims to compare the efficacy and safety of MIL62 combined lenalidomide&#xD;
      and lenalidomide alone to treat patient diagnosed with Follicular Lymphoma (FL) and&#xD;
      refractory to rituximab. The study randomized patients with a 1:1 ratio to receive either&#xD;
      MIL62 plus lenalidomide or lenalidomide.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (per IRC)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (per Investigator)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of randomization Until date of death from any cause for up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of Duration of Response</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Disease Control</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events</measure>
    <time_frame>up to the 1 month the last dose of last subject</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Follicular Lymphoma and Marginal Zone Lymphoma</condition>
  <arm_group>
    <arm_group_label>Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>lenalinomide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide</intervention_name>
    <description>The patients confirming to the eligibility criteria will receive MIL62 from cycle 1 to cycle 30 and lenalidomide from cycle 1 to cycle 18, unless either rapid disease progression or unacceptable toxicity was observed.</description>
    <arm_group_label>Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalinomide</intervention_name>
    <description>The patients confirming to the eligibility criteria will receive lenalidomide for 18 cycles, unless either rapid disease progression or unacceptable toxicity was observed.</description>
    <arm_group_label>lenalinomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult patients, &gt;=18 years of age;&#xD;
&#xD;
          2. Patients with either histologically documented CD20-positive FL, WHO grade 1, 2 or 3a&#xD;
&#xD;
          3. Evidence of refractory to rituximab&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2&#xD;
&#xD;
          5. At least one bi-dimensionally measurable nodal or tumor lesion defined by CT scan as:&#xD;
             greatest transverse diameter &gt; 1.5 cm and a short axis â‰¥ 10mm&#xD;
&#xD;
          6. Adequate hematologic function&#xD;
&#xD;
          7. Life expectancy &gt;5 years&#xD;
&#xD;
          8. Able and willing to provide written informed consent and to comply with the study&#xD;
             protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of refractory to lenalinomide&#xD;
&#xD;
          2. Central nervous system lymphoma&#xD;
&#xD;
          3. Patients with progressive multifocalleukoencephalopathy (PML)&#xD;
&#xD;
          4. Prior use of any antibody therapy(except for Rituximab ) within 3 months of study&#xD;
             start&#xD;
&#xD;
          5. Prior use of any anti-cancer vaccine&#xD;
&#xD;
          6. Prior administration of radiotherapy 42 days prior to study entry&#xD;
&#xD;
          7. Prior administration of chemotherapy 28 days prior to study entry&#xD;
&#xD;
          8. History of prior malignancy within the last 3 years, with the exception of curatively&#xD;
             treated basal or squamous cell carcinoma of the skin and low-grade in situ carcinoma&#xD;
             of the cervix&#xD;
&#xD;
          9. History of severe allergic or anaphylactic reactions to monoclonal antibody therapy&#xD;
&#xD;
         10. Known hypersensitivity to thalidomide or lenalidomide&#xD;
&#xD;
         11. Regular treatment with corticosteroids prior to the start of cycle 1, unless&#xD;
             administered for indications other than NHL at a dose equivalent to &lt; 20 mg/day&#xD;
             prednisone&#xD;
&#xD;
         12. Any serious active disease or co-morbid medical condition (such as New York Heart&#xD;
             Association Class II or IV cardiac disease, severe arrhythmia, myocardial infarction&#xD;
             within the last 6 months, unstable arrhythmias, or unstable angina) or pulmonary&#xD;
             disease (including obstructive pulmonary disease and history of bronchospasm or other&#xD;
             according to investigator's decision)&#xD;
&#xD;
         13. Infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis&#xD;
             C(including HBsAg,HBcAb positive with abnormal HBV DAN or HCV RNA )&#xD;
&#xD;
         14. Pregnant or lactating females&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuankai Shi, doctor</last_name>
    <phone>8610-87788293</phone>
    <email>syuankaipumc@126.com</email>
  </overall_contact>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 5, 2021</study_first_submitted>
  <study_first_submitted_qc>April 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

